Bionano laboratories announces publication of the largest study to-date evaluating clinical utility of optical genome mapping across multiple hematologic malignancies

In 58% or 303 of 519 cases, optical genome mapping (ogm) revealed somatic aberrations that were not detected by the standard cytogenetic workup (scgw), including tier 1, tier 2 and tier 3 structural variants (svs) and copy number variants (cnvs) in 15% or 75 of 519 cases, ogm identified additional tier 1 variants with detection rates varying by disease type, ranging from 52% in t-all to 0% in mpn. every tier 1 sv or cnv detected by ogm had direct diagnostic, prognostic, or therapeutic significance, meaning that the detection would provide additional clinical utility san diego, may 13, 2025 (globe newswire) -- bionano laboratories, a wholly-owned subsidiary of bionano genomics, inc. (nasdaq: bngo) that offers clia-certified laboratory developed tests (ldts) based on optical genome mapping (ogm), today announced a publication from the university of texas md anderson cancer center describing the largest study to-date to evaluate the clinical utility of ogm as an additional tool in the standard cytogenetic workup (scgw) of hematologic malignancies.
BNGO Ratings Summary
BNGO Quant Ranking